Circulating Tumor Cells as a Novel Prostate Cancer Diagnostic Tool

The current screening-test for prostate cancer (PCa) has the weak point of high false negative rate and a low true positive rate. There is an extreme need to a new and accurate testing system. Circulating Tumor Cells (CTCs) as the main liquid biopsy components providean excellent biomarker for early diagnosis of PCa, prognosis, recurrence risk, and treatment efficacy. This tumor cells can get release of tumor and freely circulate in the patient’s body fluids and easily are traceable to answer the presence of the tumor more that its stage.  The new gifted ISET®-CTC Test is a simple blood test with high sensitivity and specificity for the detection of CTC in PCa. As a novel idea it is a  chllengable point nowadays that it  needs further studies.